LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Oxford University’s Rapid COVID-19 Test Detects SARS-CoV-2 Within 30-45 Minutes

By LabMedica International staff writers
Posted on 17 Jul 2020
Image: Oxford University’s Rapid COVID-19 Test Detects SARS-CoV-2 Within 30-45 Minutes (Photo courtesy of University of Oxford)
Image: Oxford University’s Rapid COVID-19 Test Detects SARS-CoV-2 Within 30-45 Minutes (Photo courtesy of University of Oxford)
Scientists have developed a rapid test which detects the presence of the SARS-CoV-2 virus and could be adapted for use in settings ranging from community care, schools, airports or home self-testing.

The test for the detection of COVID-19 has been developed by the University of Oxford’s Department of Engineering Science and Oxford Suzhou Centre for Advanced Research (OSCAR Oxford, UK). The Oxford-OSCAR team has designed primers with high specificity to confirm presence of the virus in infected people, adapted from an established technology known as RT-LAMP (reverse transcription-loop mediated isothermal amplification). It is a simplified one-step version of a viral RNA test and can be used in the field without specialist equipment or training. The simple colorimetric result is read by eye or fluorescent display, meaning there is no need for additional tools to analyze results. A Bluetooth-linked fluorescent detection instrument can link the test result into a laboratory information system, so that test results can be tracked.

The test produces results within 30-45 minutes and detects SARS-CoV-19 with great sensitivity and specificity using throat/nasal swabs directly to identify individuals carrying the virus. Clinical trials have generated comparable results with laboratory tests, demonstrating reliability, and the results will be published shortly. The test will soon be certified with CE-mark. It will be available in quantity with the commercial product name Oxsed RaViD Direct at a cost of no more than GBP 20 per test, which is considerably cheaper than most of the products currently on market.

“By designing the specific primers and controlling the biochemical reaction, we are able to eliminate the non-specific reactions that cause false positives and make our RT-LAMP test robust. And the Oxford test can be transported and stored at ambient temperature without need for cold chain, which makes shipping and distribution much easier,” said Professor Wei Huang who designed the primers to target the viral RNA.

“Our test is ideal for use in community or field settings by lay persons and allows immediate decisions to be made. Immediate applications are: returning to work/education (i.e. schools, universities, companies) and making quarantine decision (e.g. care homes, hospitals, temporary migrants, tourists). Use of such a test could be crucial to economic recovery globally,” said Prof Zhanfeng Cui, the Director of OSCAR.

Related Links:
University of Oxford

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more